<DOC>
	<DOCNO>NCT00373256</DOCNO>
	<brief_summary>To compare treatment SU011248 plus paclitaxel versus bevacizumab plus paclitaxel determine treatment work well breast cancer</brief_summary>
	<brief_title>A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>On May 27 , 2009 , independent Data Monitoring Committee ( DMC ) review progress Study A6181094 . The DMC determine Study A6181094 meet pre-specified futility criterion unlikely meet primary endpoint demonstrate statistically significant improvement progression-free survival ( PFS ) patient treat sunitinib plus paclitaxel versus bevacizumab plus paclitaxel . Pfizer notify clinical trial investigator involve study regulatory agency finding . Enrollment study stop .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Diagnosis advance breast cancer . Measurable disease per RECIST ( Response Evaluation Criterion ) Solid Tumors boneonly disease . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 . No prior treatment cytotoxics advance disease set . HER2/neu positive disease unless trastuzumab previously receive contraindicate . Treatment taxane adjuvant set unless disease free interval &gt; 12 month end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>sunitinib</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>Phase 3</keyword>
</DOC>